[1] |
Randi G, Franceschi S, la Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors[J]. Int J Cancer, 2006, 118(7):1591-1602.
|
[2] |
Kalra N, Suri S, Gupta R, et al. MDCT in the staging of gallbladder carcinoma[J]. AJR Am J Roentgenol, 2006, 186(3):758-762.
|
[3] |
Lee SE, Kim KS, Kim WB, et al. Practical guidelines for the surgical treatment of gallbladder cancer[J]. J Korean Med Sci, 2014, 29(10):1333-1340.
|
[4] |
Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5, 584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan[J]. J Hepatobiliary Pancreat Surg, 2009, 16(1):1-7.
|
[5] |
Pawlik TM, Choti MA. Biology dictates prognosis following resection of gallbladder carcinoma: sometimes less is more[J]. Ann Surg Oncol, 2009, 16(4):787-788.
|
[6] |
Macias RIR, Banales JM, Sangro B, et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B):1468-1477.
|
[7] |
Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer[J]. World J Gastroenterol, 2014, 20(14):4085-4092.
|
[8] |
Spinelli A, Schumacher G, Pascher A, et al. Extended surgical resection for xanthogranulomatous cholecystitis mimicking advanced gallbladder carcinoma: a case report and review of literature[J]. World J Gastroenterol, 2006, 12(14):2293-2296.
|
[9] |
Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions[J]. Am J Surg, 2009, 198(3):333-339.
|
[10] |
Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9-tumor marker: past, present, and future[J]. World J Gastrointest Surg, 2020, 12(12):468-490.
|
[11] |
Badea R, Zaro R, Opincariu I, et al. Ultrasound in the examination of the gallbladder - a holistic approach: grey scale, Doppler, CEUS, elastography, and 3D[J]. Med Ultrason, 2014, 16(4):345-355.
|
[12] |
Gerstenmaier JF, Hoang KN, Gibson RN. Contrast-enhanced ultrasound in gallbladder disease: a pictorial review[J]. Abdom Radiol, 2016, 41(8):1640-1652.
|
[13] |
Xie XH, Xu HX, Xie XY, et al. Differential diagnosis between benign and malignant gallbladder diseases with real-time contrast-enhanced ultrasound[J]. Eur Radiol, 2010, 20(1):239-248.
|
[14] |
Zhang HP, Bai M, Gu JY, et al. Value of contrast-enhanced ultrasound in the differential diagnosis of gallbladder lesion[J]. World J Gastroenterol, 2018, 24(6):744-751.
|
[15] |
Ramachandran A, Srivastava DN, Madhusudhan KS. Gallbladder cancer revisited: the evolving role of a radiologist[J]. Br J Radiol, 2021, 94(1117):20200726.
|
[16] |
Ohtani T, Shirai Y, Tsukada K, et al. Spread of gallbladder carcinoma: CT evaluation with pathologic correlation[J]. Abdom Imaging, 1996, 21(3):195-201.
|
[17] |
Kalra N, Gupta P, Singhal M, et al. Cross-sectional imaging of gallbladder carcinoma: an update[J]. J Clin Exp Hepatol, 2019, 9(3):334-344.
|
[18] |
Schwartz LH, Black J, Fong Y, et al. Gallbladder carcinoma: findings at MR imaging with MR cholangiopancreatography[J]. J Comput Assist Tomogr, 2002, 26(3):405-410.
|
[19] |
Albazaz R, Patel CN, Chowdhury FU, et al. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours[J]. Insights Imaging, 2013, 4(5):691-700.
|
[20] |
Fogel EL, DeBellis M, McHenry L, et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study[J]. Gastrointest Endosc, 2006, 63(1):71-77.
|
[21] |
Schoefl R, Haefner M, Wrba F, et al. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses[J]. Scand J Gastroenterol, 1997, 32(4):363-368.
|
[22] |
徐庆成, 陈娟, 朱滢, 等. 内镜逆行胰胆管造影术在胆囊癌合并恶性梗阻性黄疸中的临床应用价值[J]. 中国内镜杂志, 2022, 28(8):74-78.
|
[23] |
Hijioka S, Hara K, Mizuno N, et al. Diagnostic yield of endoscopic retrograde cholangiography and of EUS-guided fine needle aspiration sampling in gallbladder carcinomas[J]. J Hepatobiliary Pancreat Sci, 2012, 19(6):650-655.
|
[24] |
Abdelghani YA, Arisaka Y, Masuda D, et al. Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields[J]. J Hepatobiliary Pancreat Sci, 2012, 19(4):370-378.
|
[25] |
Shotton R, Lamarca A, Valle J, et al. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: a review[J]. World J Gastrointest Oncol, 2021, 13(9):1073-1085.
|
[26] |
王楚风, 蒋安. 原发性肝癌的分子诊断[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(5):499-503.
|
[27] |
Salvi S, Gurioli G, de Giorgi U, et al. Cell-free DNA as a diagnostic marker for cancer: current insights[J]. Onco Targets Ther, 2016, 9: 6549-6559.
|
[28] |
Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection[J]. Genomics Proteomics Bioinformatics, 2017, 15(2):59-72.
|
[29] |
Zill OA, Greene C, Sebisanovic D, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas[J]. Cancer Discov, 2015, 5(10):1040-1048.
|
[30] |
Kumari S, Husain N, Agarwal A, et al. Diagnostic value of circulating free DNA integrity and global methylation status in gall bladder carcinoma[J]. Pathol Oncol Res, 2019, 25(3):925-936.
|
[31] |
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic-implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18: 297-312.
|
[32] |
Driescher C, Fuchs K, Haeberle L, et al. Bile-based cell-free DNA analysis is a reliable diagnostic tool in pancreatobiliary cancer[J]. Cancers, 2020, 13(1):39.
|
[33] |
Shen N, Zhang D, Yin L, et al. Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer[J]. Oncol Rep, 2019, 42(2):549-560.
|
[34] |
Jusakul A, Khuntikeo N, Haigh W, et al. Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma[J]. Asian Pac J Cancer Prev, 2012, 13 Suppl:77-82.
|
[35] |
闫甲, 刘双池, 王政宇. 胆囊癌肿瘤标志物的研究和应用进展[J/OL]. 中华普通外科学文献(电子版), 2023, 17(5):391-394.
|